CytomX Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 11, 2024. This filing reports annual results, not standalone fourth-quarter results. CytomX is a clinical-stage oncology biotechnology company developing conditionally activated biologics through its PROBODY platform. It has no approved products and has generated no product-sales revenue.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue, primarily collaborations | $101.2 million | $53.2 million |
| Research and development expense | $77.7 million | $111.6 million |
| General and administrative expense | $30.0 million | $42.8 million |
| Operating loss | $6.5 million | $101.3 million |
| Interest income | $9.8 million | $1.7 million |
| Net loss | $0.6 million | $99.3 million |
| Net loss per share, basic and diluted | $0.01 | $1.51 |
| Cash used in operating activities | $56.0 million | $110.8 million |
Revenue rose 90% year over year, led by Bristol Myers Squibb (BMS), Astellas, and revenue recognized under the newer Regeneron and Moderna collaborations; AbbVie revenue declined following termination of its agreements. Lower R&D and G&A expenses reflected the 2022 workforce reduction and winding down work on CX-2009 and CX-2029, partly offset by CX-2051 and CX-801 development costs. FY2023 moved close to break-even, but remained loss-making from operations; interest income helped offset the operating loss, while a $3.9 million California tax provision contributed to the net loss. Gross margin is not a meaningful product metric because revenue is collaboration-based and the company has no product sales.
At year-end, cash and cash equivalents were $17.2 million and short-term investments were $157.3 million, totaling approximately $174.5 million in cash, cash equivalents, and investments. Total assets were $201.8 million, total liabilities $249.2 million, and stockholders’ deficit $47.4 million. The balance sheet does not report conventional borrowings; operating lease liabilities totaled approximately $14.0 million. Management said current resources were expected to fund planned operations into the second half of 2025, while warning that the estimate depends on operating results, spending, and financing. Investing cash outflow of $150.7 million largely reflected purchases of short-term investments, rather than operating burn. Financing provided $30.2 million, mainly from the July 2023 private placement.
Material changes and business developments
- Revenue increased by $48.1 million, while R&D expense fell by $34.0 million and G&A expense fell by $12.8 million versus FY2022.
- The July 2023 private placement generated approximately $29.7 million net proceeds and included pre-funded warrants for 14.4 million shares plus warrants for up to 11.5 million additional shares. The pre-funded warrants are exercisable at $0.00001 per share, subject to beneficial ownership limits; exercise would dilute existing holders.
- AbbVie ended its CX-2029 and discovery collaborations in 2023. CytomX regained CX-2029 rights but said it did not plan significant near-term investment in the solid-tumor program.
- After year-end, in January 2024, the FDA allowed CX-2051 and CX-801 INDs to proceed. The company expected Phase 1 starts for both in the first half of 2024. CX-904, partnered with Amgen, remained in Phase 1 dose escalation, with initial Phase 1a data expected in the second half of 2024.
- On March 6, 2024, BMS said it would not develop BMS-986288 beyond the ongoing Phase 2 study and ended its work on the CTLA-4 target. CytomX reported potential BMS milestones of approximately $1.8 billion after this change, versus approximately $2.1 billion at year-end; these are contingent and were excluded from recognized transaction price.
Outlook, risks, and unusual items
- Management’s stated cash runway extends into the second half of 2025, but CytomX expects to need additional funding. It may pursue collaborations, equity, or debt financing; equity issuance and warrant exercise could dilute shareholders.
- Clinical-stage programs carry substantial efficacy, safety, enrollment, regulatory, and execution uncertainty. CX-904 is early-stage; CX-2051 and CX-801 were expected to begin first-in-human testing in 2024, subject to readiness and trial progress.
- A contract manufacturer experienced CX-2051 production failures beginning in October 2023. CytomX relies on third parties, often sole-source suppliers, has no manufacturing facilities, and reported no current alternative to certain manufacturers. CX-801 also relies on a manufacturer in China; proposed U.S. BIOSECURE legislation could create additional supply or collaboration uncertainty if enacted.
- California proposed an assessment concerning revenue apportionment for 2017–2018 collaboration payments. CytomX recorded a $3.9 million liability for the assessment, penalties, and interest and filed a protest; resolution timing is uncertain.
- Vytacera Bio’s patent-infringement case seeks unspecified damages. A magistrate recommended granting CytomX’s motion to dismiss in October 2023; the case remained stayed pending the trial judge’s ruling. No liability accrual was recorded.
- The filing states that a prior material weakness in revenue-recognition controls, identified in connection with the 2022 financial statements, was remediated by June 30, 2023. Management reported effective disclosure controls and internal control over financial reporting at year-end. The filing indicates the financial statements reflect a correction of error, but the supplied text does not clearly quantify its financial-statement effect.
- Auditors issued an unmodified opinion on the financial statements. They identified collaboration revenue accounting as a critical audit matter, involving judgments about performance obligations, consideration allocation, and estimated effort under the input method.
Important facts for investors to verify
- Whether the stated runway into the second half of 2025 remains supportable under current clinical, manufacturing, and operating plans—and what financing may be needed.
- Warrant exercise terms, potential dilution, and the fully diluted share count; 67.7 million common shares were outstanding at February 29, 2024, excluding 14.4 million shares issuable under pre-funded warrants.
- Resolution of CX-2051 manufacturing problems and the availability, timing, and quality of clinical supplies for CX-2051, CX-801, and CX-904.
- Progress and safety findings from CX-904 dose escalation and whether CX-2051 and CX-801 entered Phase 1 on the anticipated schedule.
- The impact of BMS’s CTLA-4 decision on collaboration revenue, future development support, and the remaining programs and contingent milestone opportunities.
- Outcome and potential financial consequences of the California tax assessment and Vytacera litigation, and the details of the prior-period revenue-recognition correction.